Skip to main content
Premium Trial:

Request an Annual Quote

Denis Burger, Jack Bowman

Premium
Antisense drug firm AVI BioPharma said this week that chairman and CEO Denis Burger has resigned.
 
In a statement, Burger said he is retiring.
 
Jack Bowman, AVI’s independent lead director, has been named chairman, while another independent director, Michael Forrest, has been named interim CEO.
 
"Denis Burger has made a tremendous contribution to the growth and development of AVI,” Bowman said in a statement. "The board has full confidence in AVI's executive team and we look forward to working with Mike Forrest in selecting a new leader to expand the company's footprint, accelerate selection and development of clinical candidates, and improve our market opportunities."

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.